AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Medtronic Receives Hold Rating from Wolfe Research
ByAinvest
Monday, Aug 25, 2025 10:46 am ET1min read
Wolfe Research analyst Michael Polark reiterated a Hold rating on Medtronic, citing the company's latest earnings release for the quarter ending July 25, which reported a quarterly revenue of $8.58 billion and a net profit of $1.04 billion. Polark has a 4-star rating and a 51.81% success rate, according to TipRanks.
Medtronic plc (MDT) reported robust financial results for its first quarter (Q1) of fiscal year 2026 (FY26), ending July 25, 2025. The company reported revenue of $8.578 billion, a 8.4% increase as reported and 4.8% organic growth, compared to the same period last year [1]. The adjusted revenue was $8.539 billion, with organic revenue growth of 4.8% [1].Key highlights include:
- Cardiac Ablation Solutions revenue increased nearly 50%, driven by a 72% increase in the U.S. market, largely due to the strength of pulsed field ablation (PFA) products [1].
- The U.S. Centers for Medicare & Medicaid Services (CMS) proposed a National Coverage Determination (NCD) for the Symplicity Spyral system for hypertension, with a final NCD expected by October 8, 2025 [1].
- Medtronic received CE Mark approval for LigaSure™ RAS vessel-sealing technology on the Hugo™ robotic-assisted surgery (RAS) system [1].
Medtronic's Q1 GAAP operating profit and operating margin were $1.445 billion and 16.8%, respectively, up 13% and 70 basis points year-over-year [1]. Non-GAAP operating profit and operating margin were $2.016 billion and 23.6%, respectively, up 3% and down 80 basis points [1].
The company raised its FY26 EPS guidance to the range of $5.60 to $5.66 per share, from the prior range of $5.50 to $5.60, and expects FY26 organic revenue growth of approximately 5% [1]. This increase is attributed to unexpectedly strong Q1 results and a lessened impact of tariffs.
Wolfe Research analyst Michael Polark reiterated a Hold rating on Medtronic, citing the company's latest earnings release [2]. Polark has a 4-star rating and a 51.81% success rate, according to TipRanks [2].
References:
[1] https://www.todaysmedicaldevelopments.com/news/medtronic-reports-first-quarter-fiscal-2026-financial-results/
[2] https://www.ainvest.com/news/medtronic-reports-q1-2025-earnings-sales-reach-8-578bn-net-income-1-04bn-2508/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet